Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -2.7%	$0.19	$0.05 ▼ $1.33	$15.51M	2.18	87.73 million shs	25.99 million shs
BYSI BeyondSpring	$1.76	$2.23	$0.98 ▼ $3.44	$70.99M	0.26	27,658 shs	26,529 shs
CRDL Cardiol Therapeutics	$1.17	$1.31	$0.77 ▼ $2.63	$97.94M	1.05	1.34 million shs	1.35 million shs
SRZN Surrozen	$11.22 -1.1%	$9.46	$5.90 ▼ $18.17	$97.18M	0.6	14,779 shs	7,857 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+2.45%	-19.75%	-78.58%	-79.11%	-95.08%
BYSI BeyondSpring	+2.33%	-12.44%	-5.88%	+1.79%	-6.88%
CRDL Cardiol Therapeutics	+0.86%	-12.69%	-16.43%	+6.36%	-42.65%
SRZN Surrozen	-1.30%	+4.61%	+31.21%	+42.59%	+54.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.1631 of 5 stars	3.0	3.0	0.0	0.0	2.9	1.7	0.0
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	2.6452 of 5 stars	3.7	2.0	0.0	0.0	3.9	0.0	0.6
SRZN Surrozen	2.7942 of 5 stars	3.5	2.0	0.0	0.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	2,275.51% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	583.76% Upside
SRZN Surrozen	3.00	Buy	$38.50	243.14% Upside

Current Analyst Ratings Breakdown

Latest ADAP, SRZN, CRDL, and BYSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.08	N/A	N/A	($0.27) per share	-0.21
BYSI BeyondSpring	$1.75M	40.56	N/A	N/A	($0.44) per share	-4.00
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
SRZN Surrozen	$10.65M	9.02	N/A	N/A	$5.50 per share	2.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.65	N/A	N/A	N/A	-260.82%	-163.73%	-75.83%	N/A
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/6/2025 (Estimated)
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-232.26%	-158.19%	N/A
SRZN Surrozen	-$63.56M	-$14.42	N/A	N/A	N/A	-274.42%	-545.43%	-64.40%	11/5/2025 (Estimated)

Latest ADAP, SRZN, CRDL, and BYSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	-$0.07	+$0.04	-$0.07	N/A	N/A
8/13/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.15	-$0.11	+$0.04	-$0.11	$11.04 million	$13.68 million
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/8/2025	Q2 2025	SRZN Surrozen	-$1.23	-$1.14	+$0.09	$2.55	N/A	$0.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	1.52	1.29
BYSI BeyondSpring	N/A	2.19	2.19
CRDL Cardiol Therapeutics	0.01	2.46	3.26
SRZN Surrozen	N/A	16.41	16.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
BYSI BeyondSpring	40.29%
CRDL Cardiol Therapeutics	12.49%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
BYSI BeyondSpring	29.31%
CRDL Cardiol Therapeutics	5.25%
SRZN Surrozen	45.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
BYSI BeyondSpring	80	40.33 million	28.51 million	Optionable
CRDL Cardiol Therapeutics	20	83.71 million	79.32 million	Not Optionable
SRZN Surrozen	80	8.56 million	4.69 million	Not Optionable

ADAP, SRZN, CRDL, and BYSI Headlines

Recent News About These Companies

HC Wainwright Issues Positive Forecast for Surrozen Earnings

August 16, 2025 | marketbeat.com

HC Wainwright Issues Positive Estimate for Surrozen Earnings

August 16, 2025 | americanbankingnews.com

Surrozen (NASDAQ:SRZN) Issues Earnings Results

August 11, 2025 | marketbeat.com

Vivo Capital LLC Takes Position in Surrozen, Inc. (NASDAQ:SRZN)

August 9, 2025 | marketbeat.com

Surrozen (NASDAQ:SRZN) Stock Price Down 12.8% - Should You Sell?

August 9, 2025 | marketbeat.com

Surrozen’s Q2 2025: Progress in Eye Disease Therapies

August 8, 2025 | tipranks.com

Surrozen Reports Q2 Profit on Gains

August 8, 2025 | fool.com

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

August 8, 2025 | globenewswire.com

Surrozen to Present at Upcoming Healthcare Investor Conference

August 6, 2025 | globenewswire.com

Surrozen (SRZN) Projected to Post Earnings on Monday

August 5, 2025 | marketbeat.com

We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth

July 1, 2025 | finance.yahoo.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 1, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, SRZN, CRDL, and BYSI Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.06 0.00 (-2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$0.06 +0.00 (+2.11%)

As of 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

BeyondSpring NASDAQ:BYSI

$1.76 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.85%)

As of 07:59 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Cardiol Therapeutics NASDAQ:CRDL

$1.17 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 0.00 (-0.09%)

As of 07:56 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Surrozen NASDAQ:SRZN

$11.22 -0.13 (-1.15%)

As of 04:00 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time